Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2021 Feb 9;9(3):1694-1698.
doi: 10.1002/ccr3.3878. eCollection 2021 Mar.

Larotrectinib in a NTRK-rearranged soft tissue sarcoma in the neoadjuvant setting: A case report

Catherine Percy  1 , Thomas Schubert  1 , Christine Galant  1 , Thomas Kirchgesner  1 , Filomena Mazzeo  1
Affiliations
Case Reports

Larotrectinib in a NTRK-rearranged soft tissue sarcoma in the neoadjuvant setting: A case report

Catherine Percy et al. Clin Case Rep. .

Abstract

Patients with soft tissue sarcomas should be assessed for neurotrophic tropomyosin receptor kinase (NTRK) gene fusions as neoadjuvant treatment with larotrectinib may prevent amputation.

Keywords: NTRK gene fusions; larotrectinib; neoadjuvant; soft tissue sarcoma.

PubMed Disclaimer

Conflict of interest statement

The authors have no conflicts of interest to disclose.

Figures

FIGURE 1
FIGURE 1
Lesion at diagnosis assessed by (A) photograph and contrast‐enhanced MRI (B) fat‐suppressed axial T1‐weighted images and (C) sagittal T1‐weighted images. MRI demonstrated a well‐defined enhancing mass of the posterior compartment of the leg surrounding the Achilles tendon (arrow) and eroding the posterior tibial cortex (arrowhead)
FIGURE 2
FIGURE 2
Photographs of the left leg (A) before and (B) after 3 mo of larotrectinib therapy
FIGURE 3
FIGURE 3
Lesion before surgery assessed by (A) photograph and contrast‐enhanced MRI (B) fat‐suppressed axial T1‐weighted images and (C) sagittal T1‐weighted images. MRI showed a significant decrease in tumor volume with large nonenhanced areas suggestive of tissue necrosis (arrows)
See this image and copyright information in PMC

References

    1. von Mehren M, Lor Randall R, Benjamin RS, et al. Soft tissue sarcoma, version 2.2018. NCCN clinical practice guidelines in oncology. J Natl Comp Canc Netw. 2018;16(5):526‐563. - PubMed
    1. Drilon A, Laetsch T, Kummar S, et al. Efficacy of larotrectinib in TRK fusion–positive cancers in adults and children. N Engl J Med. 2018;378(8):731‐739. - PMC - PubMed
    1. Amatu A, Sartore‐Bianchi A, Bencardino K, et al. Tropomyosin receptor kinase (TRK) biology and the role of NTRK gene fusions in cancer. Ann Oncol. 2019;30(Supplement_8):viii5‐viii15. - PMC - PubMed
    1. Amatu A, Sartore‐Bianchi A, Siena S. NTRK gene fusions as novel targets of cancer therapy across multiple tumour types. ESMO Open. 2016;1(2):e000023. - PMC - PubMed
    1. Gatalica Z, Xiu J, Swensen J, et al. Molecular characterization of cancers with NTRK gene fusions. Mod Pathol. 2019;32(1):147‐153. - PubMed

Publication types

LinkOut - more resources